Bexotegrast
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2019 (NCT04072315)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Integrin alpha-V/betaINHIBITOR
Integrin alpha-V/beta inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCN(CCCCC1=CC=C2CCCN=C2N1)CC[C@H](Nc1ncnc2ccccc12)C(=O)O- Mol. weight
- 492.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095257 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06097260 | Phase 2 | Nov 16, 2023 | Pliant Therapeutics |
| NCT05621252 | Phase 2 | Jul 13, 2022 | Harvard University, Pliant Therapeutics |
| NCT04565249 | Phase 2 | Oct 22, 2020 | Pliant Therapeutics |
| NCT04480840 | Phase 2 | Jul 27, 2020 | Pliant Therapeutics |
| NCT04396756 | Phase 2 | Mar 3, 2020 | Pliant Therapeutics |
| NCT04072315 | Phase 2 | Sep 9, 2019 | Pliant Therapeutics, Stanford University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pliant Therapeutics | For profit | 6 | 6 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1